CohBar Says On Nov 1, Got Termination Notice From Morphogenesis, Effective Nov 1 And Merger Agreement Was Terminated In Accordance With Terms
$CWBR
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Health Care
-SEC 8K Filing
-SEC 8K Filing
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/11/2021 | $5.00 | Speculative Buy → Buy | WBB Securities |
WBB Securities upgraded CohBar from Speculative Buy to Buy and set a new price target of $5.00
Maxim Group initiated coverage of CohBar with a rating of Buy and set a new price target of $3.00
Aegis Capital initiated coverage of CohBar with a rating of Buy and set a new price target of $6.00
25-NSE - CohBar, Inc. (0001522602) (Subject)
8-K - CohBar, Inc. (0001522602) (Filer)
8-K - CohBar, Inc. (0001522602) (Filer)
SC 13G/A - CohBar, Inc. (0001522602) (Subject)
SC 13G/A - CohBar, Inc. (0001522602) (Subject)
SC 13G/A - CohBar, Inc. (0001522602) (Subject)
MENLO PARK, Calif., July 12, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today announced the appointment of Effie Tozzo, Ph.D. as an independent director on the company's Board, effective July 11, 2022. Dr. Tozzo brings extensive research and development experience at both established pharmaceutical and innovative biotechnology companies. "We are delighted to add Dr. Tozzo to our Board and will tap into her considerable expertise in advancing preclinical assets to the clini
Founding board members transition to reconstituted Scientific Advisory Board Kent Grindstaff, Ph.D. appointed as Senior Vice President of Research MENLO PARK, Calif., Dec. 17, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced changes to its Board of Directors, Scientific Advisory Board (SAB), and R&D leadership. CohBar's founders Drs. Nir Barzilai, Pinchas Cohen, and John Amatruda have transitioned from the company's Board of Directors to a reconstituted SAB. The SAB will be comprised of experts in mitochondrial science and other dis
MENLO PARK, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced the appointment of Joanne Yun, Ph.D. as an independent director on the company's Board, effective September 14, 2021. Dr. Yun brings extensive research and development, commercial, and governance experience from the pharmaceutical industry. "We are very pleased to add Dr. Yun as an independent director and look forward to her strategic input as we continue to develop our diverse pipeline of novel mitochondria based therapeutics," said David Greenwood, Chair
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 20, 2023, CohBar, Inc. (the "Company") was notified by the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") of its determination pursuant to Nasdaq Listing Rule 5101 that, based upon the Staff's belief that the Company is a "public shell," and that the continued listing of the Company's securities is no longer warranted, and the Company's non-compliance with certain board and committee composition listing requirements under Nasdaq Listing Rule 5605 and certain of Nasdaq's filing requirements under Nasdaq Listing Rule 5250(c)(1)
MENLO PARK, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) today reported its financial results and highlights for the second quarter ended June 30, 2023. Second Quarter 2023 Summary and Financial Results Entered into Definitive Merger Agreement with Morphogenesis: In May 2023, CohBar announced that the company entered into a definitive merger agreement with a privately held biotechnology company, Morphogenesis, Inc. ("Morphogenesis"), for an all-stock transaction to advance a late-stage oncology pipeline. The combined company is expected to operate under the name "TuHURA Biosciences, Inc." and to trade on The Nasdaq Capital Market ("Nasdaq"). The transaction is exp
IFx-Hu2.0 demonstrated to have a promising safety profile at all 3 dose schedules tested 5 of 7 (71%) of patients achieved durable systemic anti-tumor responses following IFx-Hu2.0 therapy and rechallenge with an immune checkpoint inhibitor (ICI) in patients who exhibited primary resistance to ICIs Translational biomarker data underscores IFx-Hu2.0 mechanism; Demonstrates activation of systemic tumor-specific immune responses Data presented at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting TAMPA, Fa. and MENLO PARK, Calif., June 05, 2023 (GLOBE NEWSWIRE) -- Morphogenesis, Inc. ("Morphogenesis"), a privately-held Phase 2/3 clinical-stage biotechnology compa
4 - CohBar, Inc. (0001522602) (Issuer)
4 - CohBar, Inc. (0001522602) (Issuer)
4 - CohBar, Inc. (0001522602) (Issuer)
NEW YORK, June 03, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) Lifshitz Law PLLC announces an investigation into possible breach of fiduciary duties in connection with the merger of CWBR and Morphogenesis, Inc. Under the terms of the proposed merger, CWBR shareholders will receive a dividend equal to approximately 3.30 shares of CWBR common stock. Following the merger, pre-merger CohBar shareholders are expected to own approximately 15% of the outstanding equity of the combined company. If you are a CWBR investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq. by telephone at (516)493-
Combined company will operate under the name "TuHURA Biosciences, Inc." and advance a personalized cancer vaccine platform and preclinical tumor microenvironment modulatorsLead asset, IFx-Hu2.0, expected to enter Phase 2/3 registration trial as first-line treatment for Merkel Cell Carcinoma in early 2024$15 million PIPE financing to close concurrent with the closing of the proposed merger – combined company expected to have cash runway through 2024Companies to hold a joint conference call and webcast today, Tuesday, May 23rd at 8:30 AM ET MENLO PARK, Calif. and TAMPA, Fla. , May 23, 2023 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR) ("CohBar" or the "company") and Morphogenesis, Inc. ("M
MENLO PARK, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- CohBar, Inc. (NASDAQ:CWBR), a clinical stage biotechnology company leveraging the power of the mitochondria and the peptides encoded in its genome to develop potential breakthrough therapeutics targeting chronic and age-related diseases, today reported its financial results for the third quarter ended September 30, 2022 and highlighted recent corporate progress. "I'm pleased with the team's performance during the third quarter of 2022 in advancing our top priorities, including improving the formulation of CB5138-3, our product candidate for IPF," stated Dr. Joseph Sarret, Chief Executive Officer. "We continue to operate the company i
Gainers 180 Life Sciences (NASDAQ:ATNF) shares rose 38.2% to $0.47 during Tuesday's after-market session. The company's market cap stands at $3.4 million. Redhill Biopharma (NASDAQ:RDHL) shares rose 23.34% to $2.8. The market value of their outstanding shares is at $30.9 million. Trinity Biotech (NASDAQ:TRIB) stock rose 15.25% to $0.52. The company's market cap stands at $19.8 million. Blue Water Biotech (NASDAQ:BWV) shares increased by 13.04% to $0.26. The market value of their outstanding shares is at $4.8 million. CohBar (NASDAQ:CWBR) shares increased by 12.96% to $0.86. The market value of their outstanding shares is at $2.4 million. DermTech (NASDAQ:DMTK) stock moved upwards by 9.
Shares of SenesTech, Inc. (NASDAQ:SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering. SenesTech company priced a public offering of around 3.8 million shares of common stock at $1.30 per share, alongside warrants for additional shares. SenesTech shares declined 50.3% to $0.9189 on Tuesday. Here are some other stocks moving in today's mid-day session. Gainers IceCure Medical Ltd (NASDAQ:ICCM) jumped 90% to $1.44 after the company announced the latest release of a study in a series of independent studies of ProSense published in peer-reviewed journals demonstrating safety and efficacy. RedHill Biopharma Ltd. (NASDAQ:RDH
Gainers Avidity Biosciences (NASDAQ:RNA) shares rose 38.1% to $8.51 during Tuesday's pre-market session. The market value of their outstanding shares is at $630.6 million. Heart Test Laboratories (NASDAQ:HSCS) shares moved upwards by 22.98% to $0.26. The market value of their outstanding shares is at $12.8 million. Redhill Biopharma (NASDAQ:RDHL) shares moved upwards by 17.99% to $1.18. The company's market cap stands at $13.0 million. icad (NASDAQ:ICAD) shares increased by 17.51% to $1.61. The market value of their outstanding shares is at $42.4 million. Virax Biolabs Group (NASDAQ:VRAX) stock moved upwards by 10.81% to $0.25. The market value of their outstanding shares is at $4.5 mil